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ABSTRACT
Objective: The present study deals with the formulation and evaluation of fast dissolving buccal films for effective treatment option in the 
gastroesophageal reflux disease.
Methods: Esomeprazole fast dissolving buccal films are a convenient formulation of which can be taken with or without water. In the present 
investigation, polyvinyl alcohol and polyvinylpyrrolidone were used as film-forming agents and polyethylene glycol 400 is taken as plasticizer. Solvent 
evaporation method was used for the preparation of fast dissolving buccal films.
Results: The films were prepared and evaluated for film thickness, folding endurance, dispersion test, drug content, and dissolution. The in vitro 
dissolution studies were carried out using simulated salivary fluid (pH 6.8 phosphate buffer).
Conclusion: Among all the formulations, Formulation E7 was released up to 99.6% of the drug from the film within 5 min of time which exhibits 
faster absorption and also shows desirable characteristics of the film. The drug-excipient interaction studies WERE carried out by Fourier-transform 
infrared studies, differential scanning calorimetry analysis-X-diffraction studies, and scanning electron microscopic studies and the results revealed 
that there were no major interactions between the drugs and excipients used for the preparation of films.
Keywords: Fast dissolving buccal films, Esomeprazole, Polyvinyl alcohol, Polyvinylpyrrolidone, Polyethylene glycol 400 solvent evaporation method.
INTRODUCTION
Esomeprazole, the new S-isomer of omeprazole, is introduced to 
reduce gastric acid secretion more efficiently. Esomeprazole exhibits 
significantly higher bioavailability, leading to the greater inhibition 
of gastric acid secretion compared to omeprazole [1]. Esomeprazole, 
the stereospecific S-isomer of Omeprazole, is the first proton-pump 
inhibitor to be developed as a single isomer for use in the treatment 
of acid-related diseases [2]. The intragastric pH-monitoring data for 
esomeprazole, 20 mg once daily, show improvement over omeprazole, 
20 mg once daily, but the esomeprazole, 40 mg once daily, intragastric 
pH data show a further convincing gain in control of gastric pH [3]. 
Early studies have shown that esomeprazole achieves greater and more 
sustained acid control than omeprazole, with a similar tolerability and 
safety profile. Furthermore, esomeprazole shows a more rapid onset 
of acid-suppression effect than omeprazole and less interindividual 
variation in acid control. In addition, a recent crossover study 
demonstrated that esomeprazole at a standard dose of 40 mg once 
daily provides more effective control of gastric acid at steady state 
than standard doses of pantoprazole, lansoprazole, and rabeprazole in 
patients with symptomatic gastroesophageal reflux disease (GERD) [4]. 
In addition, esomeprazole treatment yields higher erosive esophagitis 
healing rates and provides sustained resolution of heartburn in more 
patients than any other [5]. GERD is a condition in which the digestive 
acid in the stomach comes in contact with the esophagus (food pipe). 
The irritation caused by this disorder is known as heartburn. Long-
term contact between the acid and esophagus can cause permanent 
damage to the esophagus [6,7]. Esomeprazole reduces the production 
of digestives acids, thus minimizing their effect on the esophagus. 
Esomeprazole is combined with the antibiotics clarithromycin and 
amoxicillin (or metronidazole in penicillin-hypersensitive patients) 
in the 7– 14-day eradication triple therapy for Helicobacter pylori. 
Infection by H. pylori is the causative factor in the majority of peptic and 
duodenal ulcers [5].
METHODS
Esomeprazole was procured as gift sample from M/S Aurobindo 
Pharmaceuticals, Hyderabad. Polyvinyl alcohol (PVA) and 
polyvinylpyrrolidone (PVP) were commercially procured from M/S 
Yarrow Chem Products, Mumbai. Polyethylene glycol (PEG) was 
procured commercially from Sisco Research Laboratories Pvt. Ltd., 
Mumbai. Saccharin sodium was procured commercially from High-Pure 
Fine Chemicals, Chennai. All the materials used in the formulation were 
of pharmacopoeial standards.
Preparation of esomeprazole fast dissolving buccal films (EFDBF)
Fast dissolving buccal films of esomeprazole were prepared by solvent 
evaporation method. Film-forming agents such as PVA and PVP were 
prepared in the form of aqueous solutions individually in 100 ml 
beakers to attain clear solutions. Then, the solution of PVP was added 
to PVA aqueous solution and stirred well to get homogenous solution 
which is marked as solution A. Accurate quantities of esomeprazole and 
saccharin sodium were weighed individually and dissolved in suitable 
quantity of PEG 400 to get a drug and plasticizer solution which is 
marked as solution B. The solution B was added to aqueous solution 
A and mixed continuously. The obtained solution was drawn on the 
non-adhesive base plate and dried under infrared (IR) lamp for 24 h. 
After drying, the films were cut into suitable sizes [8]. Various trials 
were conducted to carried out optimize formula for the preparation of 
EFDBF. The various compositions of EFDBF are given in Table 1.
Evaluation of fast dissolving films
Film thickness
The film thickness was measured using screw gauge with a least count 
of 0.01 mm at different locations on the film. The film thickness was 
measured at three different locations, and the average weight was 
determined. The obtained results are given in Table 2.
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Folding endurance
It was determined by folding the film several times (95 times).  The film 
was found to be having good flexibility without cracking. The film was 
folded at an angle of 180° at the same place till it broke or folded up to 
100 times without breaking. The studies were performed in Trice and 
the average mean was calculated.
Uniformity of drug content
The content of drug uniformity of the films was tested by ultraviolet 
(UV)-visible spectrophotometric method. The absorbance values were 
determined at a wavelength of 300 nm. The % drug content of various 
films was determined and is given in Table 3.
Dispersion test
A film equivalent to 20 mg of esomeprazole was placed in 200 ml of 
6.8 pH phosphate buffer and was stirred for 3 min. Then, the resulting 
solution was passed through sieve number 22. The film passed the 
dispersion test only when no residue is left on the screen.
In vitro dissolution study using Franz diffusion cell
It was determined using Franz diffusion cell with an constant volume of 
buffer (15 mL) (Fig.2).. The film equivalent to 20 mg of esomeprazole was 
placed in between the two compartments of an apparatus and pipette 
15 ml of 6.8 pH buffer (pH of saliva) was added to receptor compartment. 
Cell is kept on magnetic stirrer and bead in the cell is maintained at a 
speed of 50 revolution per minute (RPM), and medium was maintained 
at a temperature of nearly 32°C±0.5°C and withdraw 1ml of samples at 
various time intervals. The samples were diluted with 6.8 pH phosphate 
buffer and measured the absorbance at 296 nm against 6.8 pH Buffer as 
Blank [9,10]. The various dissolution profiles for films are given in shown 
in Fig. 1. The in vitro dissolution parameters are given in Table 3.
Evaluation of various dissolution parameters
Based on dissolution data obtained, various dissolution parameters 
were calculated such as T50, T90, DE5% first-order rate constant, and 
Hixson–Crowell as shown in Table 3.
Characterization
Dissolution studies were performed on all the formulations, and among 
these, formulation E7 was further evaluated by Fourier-transform 
infrared (FTIR) spectroscopy and differential scanning calorimetry.
FTIR
The FTIR spectra of esomeprazole, PVP, and PVA were obtained using 
Bruker FTIR spectrophotometer to study the interaction between drug 
and carrier in films. The samples were prepared in KBr discs (2 mg 
sample in 200 mg KBr), and the sampling range was 400–4000 cm−1 and 
the resolution was 4 cm−1. The FTIR spectra are shown in Figs. 2 and 3.
Differential scanning calorimetry (DSC)
DSC measurements were performed on esomeprazole and film-
forming agents such as PVP, PVA, and optimized formulation E7 using 
Table 1: Composition of EFDBF
S.No Ingredients/10 films E1 E2 E3 E4 E5 E6 E7 E8 E9
1 Esomeprazole 200 200 200 200 200 200 200 200 200
2 PVP 300 300 300 300 300 300 300 300 300
3 PVA 350 400 450 500 550 550 550 550 550
4 PEG400 100 100 100 100 100 120 140 160 180
5 Sodium saccharine 20 20 20 20 20 20 20 20 20
6 Methanol (ml) 10 10 10 10 10 10 10 10 10
EFDBF: Esomeprazole fast dissolving buccal films, PVP: Polyvinylpyrrolidone, PVA: Polyvinyl alcohol, PEG 400: Polyethylene glycol 400
Table 2: Evaluation of in vitro dissolution parameters for EFDBF
S.No Formulation Weight  
uniformity (mg)









1. E1 84 18.777 0.034 Passed 85 Absent
2. E2 78 18.815 0.034 Passed 96 Absent
3. E3 91 18.557 0.034 Passed 92 Absent
4. E4 96 19.440 0.034 Passed 99 Absent
5. E5 88 18.745 0.033 Passed 98 Absent
6. E6 79 17.236 0.034 Passed 95 Absent
7. E7 103 19.995 0.034 Passed 105 Absent
8. E8 99 19.65 0.032 Passed 99 Absent
9. E9 70 17.5698 0.032 Passed 66 Absent
EFDBF: Esomeprazole fast dissolving buccal films
Table 3: Evaluation of physical parameters for EFDBF
S.No Formulation T50 (min) T 90 (min) DE 5% First order
K (min−1) R2
1. E1 4.6 >15 18.4 0.163 0.953
2. E2 2.5 >15 20.5 0.181 0.966
3. E3 2.4 14.5 19.8 0.156 0.946
4. E4 2.3 10 19.6 0.234 0.954
5. E5 2.2 9.5 22.4 0.216 0.951
6. E6 2.5 8.5 16.1 0.152 0.988
7. E7 0.6 4.5 27.8 0.187 0.964
8. E8 2.3 14 22.8 0.267 0.994
9. E9 2.0 14.5 24.9 0.316 0.916
EFDBF: Esomeprazole fast dissolving buccal films
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differential scanning calorimeter (SHIMZDO and DSC-60). The samples 
were placed in a sealed aluminum crucible and evaluated with a heating 
rate of 20°C/min at a temperature range of 25–250°C. The thermograms 
were recorded and are shown in Figs. 4-9.
Scanning electron microscope (SEM) analysis
The SEM photographs were taken for the optimized film formulation 
E7 and esomeprazole pure drug. The SEM photographs are shown in 
Figs. 10 and 11. The E7 formulation showed smooth even surface.
X-ray powder diffraction (XRD)
The powder crystalline of the esomeprazole and the optimized 
formulation E7 were determined using SHIMADZO XRD-7000 with copper 
target instrument. The conditions were maintained at 40 Kv, with 40 MA 
at room temperature. The scanning rate employed was 0.1/s over a range 
of 2 values from 3° to 45°. The diffractograms are shown in Figs. 12-15.
RESULTS AND DISCUSSION
The present investigation deals with the formulation and evaluation 
of fast dissolving buccal films of esomeprazole which is used for the 
treatment of acid-related disorders. The main focus on this study was 
to select the best combination of polymer and excipients to formulate 
acid-related disorders fast dissolving buccal films. Fast dissolving 
buccal films were prepared by solvent evaporation method using PVP 
and PVA. PEG 400 was used as plasticizer to make them pliable and 
flexible in nature. Saccharin sodium was used as artificial sweetener in 
the formulation. The films were prepared and evaluated for thickness, 
folding endurance; drug content uniformity and dispersion time. The 
composition of various fast dissolving buccal films of acid-related 
disorders is given in Table 1.
The prepared films were further evaluated for thickness, folding 
endurance, dispersion test, drug content, and in vitro diffusion studies. 
The thickness of a film was found in the range of 0.032±0.001–
0.034±0.004 mm. The optimized formulation E7 film is having 
thickness of 0.034 mm. The folding endurance values of all prepared 
films ranged from 30 to 100%. The optimized formulation E7 film 
was found to have the folding endurance of 100% which is highly 
beneficial or agreeable. The drug uniformity was found in the range of 
19.99±1.6 mg. The optimized formulation E7 film was found to have 
19.99 mg. The films were further subjected to dispersion test as per 
the Indian pharmacopeial standard. All the prepared film formulations 
were found to disperse in 6.8 pH phosphate buffer within 3 min. No 
inert fibrous or insoluble material was left on the 22 mesh screen 
when the dispersion was passed through it. The prepared films were 
subjected to thickness of a film, drug content, folding endurance, and 
dispersion test values obtained for various fast dissolving buccal films 
which are given in Table 3.
Fast dissolving buccal films of esomeprazole were further subjected to 
in vitro dissolution studies using Frantz diffusion cell with 15 ml of 6.8 
pH phosphate buffer as a medium which is maintained at a temperature 
32°C. The dissolution medium in the cell was maintained to rotate at 
50 rpm using magnetic stirrer. The samples were withdrawn at various 
time intervals and were consequently diluted with 6.8 pH phosphate 
buffer, and absorbance values were noted at 296 nm using ELICO 
Double beam spectrophotometer. The obtained dissolution profiles are 
given in Table 3 and are shown in Fig. 1. Among all the formulations, 
formulation E7 was found to be best suitable for fast dissolving and 
Fig. 1: (a-c) Esomeprazole fast dissolving buccal films
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also this film should possess all the physical characteristics required 
for the fast dissolving buccal film. The film formulations E7 containing 
30% of PVP and 55% of PVA were found to exhibit the best film-
forming properties with 100% folding endurance value. These 
E8 formulations with 10–16% of PEG were found to exhibit rapid 
dispersion in the dissolution media and dissolved readily in the same 
medium which indicated fast dissolving characteristics of the film. The 
first-order graphs for various fast dissolving buccal films were found 
Fig. 3: Fourier-transform infrared spectrum of esomeprazole pure drug
Fig. 4: Fourier-transform infrared spectrum of polyvinylpyrrolidone 
Fig. 5: Fourier-transform infrared spectrum of polyvinyl alcohol
Fig. 6: Differential scanning calorimetry thermogram of esomeprazole pure drug
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to be linear with correlation coefficient values obtained which were 
in the range of 0.926–0.996. It indicated that the drug release from 
the films was found to be concentration dependent. This indicated 
that the dissolution of the drug from the film was greatly dependent 
on weight uniformity of the film that undergoes dissolution per unit 
time. The formulated films were characterized using FTIR.. The FTIR 
spectra of the commercial sample of esomeprazole displayed bands at 
3206 cm−1 due to N-H Stretch and 2952 cm−1 due to C=C Stretching. 
The IR spectra of drug and film-forming agents indicated that there are 
no interactions between drug and excipients used. DSC thermographic 
studies were carried out on esomeprazole pure drug and film-forming 
agents. The exothermic peak for pure esomeprazole drug was obtained 
Fig. 7: Differential scanning calorimetry thermogram of polyvinylpyrrolidone
Fig. 8: Differential scanning calorimetry thermogram of polyvinyl alcohol
Fig. 9: Differential scanning calorimetry thermogram of optimized formulation E7
Fig. 10: Scanning electron microscope photograph of 
esomeprazole pure drug
Fig. 11: Scanning electron microscope photograph of optimized 
film formulation (E7)
198
Asian J Pharm Clin Res, Vol 11, Issue 10, 2018, 193-199
 Balakrishna et al. 
at 159.67°C. The short broad exothermic peak for PVP was obtained 
at 227.07°C. The short exothermic peak for PVA was obtained at 
161.41°C. Optimized formulation E8 was obtained at 171.59°C. Hence, 
no interaction between drug and excipients was observed with DSC 
studies.
The XRD patterns of esomeprazole and film-forming agents such as 
PVP and PVA and optimized formulation (E7) diffraction patterns of 
pure esomeprazole showed characteristic high diffraction peaks. On 
the other hand, the diffraction patterns of optimized formulation (E7) 
showed a decrease in the peak intensity.
CONCLUSION
Fast dissolving buccal films of esomeprazole prepared in the present 
study should exhibit good film properties as indicated by film thickness, 
and folding endurance was measured. All the films prepared were found 
to be stable uniform, flexible, pliable, and 99% of drug was released 
from optimized film E7 within 5 min of time. This was advisable for fast 
absorption. Hence, fast dissolving buccal films of esomeprazole were 
found to be suitable for effective and well-tolerated treatment option in 
the management of acid-related disorders
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Fig. 12: X-ray powder diffraction spectrum of esomeprazole pure drug
Fig. 13: X-ray powder diffraction spectrum of polyvinylpyrrolidone
Fig. 14: X-ray powder diffraction spectrum of polyvinyl alcohol
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Fig. 15: X-ray powder diffraction spectrum of optimized formulation (E7)
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